LOTUS: Protocol for a double-blind placebo controlled randomized trial of hemp-derived cannabidiol for the treatment of cannabis use disorder
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0308262 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS ONE, 2024. Verfasst von L Cinnamon Bidwell und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Cognitive Science, University of Colorado Boulder, Boulder, CO, United States of America. Hauptthemen laut MEDLINE: Cannabidiol, Cannabis, Marijuana Abuse. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAAA NIH HHS, NIDA NIH HHS, NIH/NIDA.
Abstract (Originalsprache)
Background
As cannabis legalization continues to spread across the United States, average Δ 9 -tetrahydrocannabinol concentrations in recreational products have significantly increased, and no prior study has evaluated effective treatments to reduce cannabis use among high potency cannabis users. Some research has found that the non-intoxicating cannabinoid cannabidiol reduces cannabis use and cannabis use disorder-related symptoms, such as affective disturbance and withdrawal. Results of these studies are promising but limited to synthetic or isolated forms of cannabidiol.
Objective
Conduct a placebo-controlled randomized control trial comparing the effects of hemp-derived cannabidiol on reducing Δ 9 -tetrahydrocannabinol use in concentrate users with cannabis use disorder.
Methods
Design. Double-blind, three-arm randomized placebo-controlled trial.
Setting
University in the Denver-Boulder, CO, USA area. Study population. Community members who are heavy, stable cannabis concentrate users that meet criteria for at least moderate cannabis use disorder and are seeking to decrease or stop cannabis use. Data. Self-report demographics, substance use, and mental health characteristics, blood and urine based biomarkers and anthropometrics. Outcomes. Affective, physiological, and physical withdrawal symptoms, Δ 9 -tetrahydrocannabinol use. Analysis. Three-group ANOVAs and χ 2 tests will be used to compare baseline variables between groups. Characteristics that differ between groups will be evaluated as potential covariates in subsequent analyses. A multilevel modeling framework will be used for primary outcome analysis to account for the repeated observations nested within participants over time. Pairwise post-hoc simple effects tests will be conducted to confirm patterns of differences.
Trial registration
ClinicalTrials.gov NCT06107062 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute for Cognitive Science, University of Colorado Boulder, Boulder, CO, United States of America.
- Psychology and Neuroscience, University of Colorado Boulder, Boulder, CO, United States of America.
- Department of Psychiatry, University of Colorado Denver, Denver, CO, United States of America.
ORCID-Profile: L Cinnamon Bidwell, Renee Martin-Willett
Förderung
- NIAAA NIH HHS
- NIDA NIH HHS
- NIH/NIDA
- National Institute on Alcohol Abuse and Alcoholism
Zitieren
APA
Bidwell, L. C., Martin-Willett, R., Melendez, S. N., Rosa, L., Giordano, G., Hutchison, K. E., & Bryan, A. D. (2024). LOTUS: Protocol for a double-blind placebo controlled randomized trial of hemp-derived cannabidiol for the treatment of cannabis use disorder. PLOS ONE. https://doi.org/10.1371/journal.pone.0308262
Vancouver
Bidwell LC, Martin-Willett R, Melendez SN, Rosa L, Giordano G, Hutchison KE, et al. LOTUS: Protocol for a double-blind placebo controlled randomized trial of hemp-derived cannabidiol for the treatment of cannabis use disorder. PLOS ONE. 2024. doi:10.1371/journal.pone.0308262
BibTeX
@article{Bidwell2024,
author = {Bidwell, L Cinnamon and Martin-Willett, Renee and Melendez, Samantha N and Rosa, Luiza and Giordano, Gregory and Hutchison, Kent E and Bryan, Angela D},
title = {LOTUS: Protocol for a double-blind placebo controlled randomized trial of hemp-derived cannabidiol for the treatment of cannabis use disorder},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0308262}
}
EUVIMED